CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Horizon Discovery has signed a research service agreement with Blueprint Medicines, a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal, Horizon will support Blueprint’s New Targets discovery platform by deploying its X-Man isogenic cell lines.
Horizon will use its proprietary platform to screen a selection of Blueprint’s kinase inhibitor tool compounds on a panel of 26 X-Man isogenic cell lines. Performing screens on X-Man cell lines will provide valuable insights into elucidating synthetic lethal interactions with approximately 100 kinase targets in various cancer subtypes.
Financial terms were not disclosed.
Horizon Discovery, 44 (0) 12 2365 5580
Blueprint Medicines, 617-374-7580